NewAmsterdam Pharma (NAMS) Revenue (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Revenue data on file, last reported at $3.0 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 2.08% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $22.6 million (down 52.13% YoY), and the FY2025 full-year result was $22.5 million, down 50.61% from the prior year.
• Revenue improved to $3.0 million in Q1 2026, from $32000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $29.1 million in Q3 2024 to a low of $32000.0 in Q4 2025.
• A 4-year average of $6.6 million and a median of $2.9 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue surged 1490.54% in 2024 and tumbled 99.75% in 2025, its largest moves.
• Tracing NAMS's Revenue over 4 years: stood at $803000.0 in 2023, then surged by 1490.54% to $12.8 million in 2024, then plunged by 99.75% to $32000.0 in 2025, then surged by 9400.0% to $3.0 million in 2026.
• Business Quant data shows NAMS's Revenue at $3.0 million in Q1 2026, $32000.0 in Q4 2025, and $348000.0 in Q3 2025.